ArticleCureus2024
Phosphaturic Mesenchymal Tumor of the Greater Trochanter: A Case Report.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Case Report: Phosphaturic mesenchymal tumor of the scapula without calcification: a potential diagnostic pitfall.Frontiers in oncology · 2026Article
- Tumor induced-osteomalacia caused by a phosphaturic mesenchymal tumor in the sartorius muscle: a case report.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This is the case of a 56-year-old Hispanic male with a history of multiple fractures and electrolyte abnormalities, including hypophosphatemia and phosphaturia. Physical examination, imaging studies, and laboratory workup may have suggested the presence of a phosphaturic mesenchymal tumor (PMT) causing osteomalacia. The patient underwent surgery for en bloc tumor removal, and the histopathological analysis confirmed the presence of neoplastic cells consistent with PMT with minimal immunohistochemical positivity to S100 protein, which is atypical for this type of tumor. This case highlights the challenges in diagnosing PMTs due to their rarity and variable presentation. It emphasizes the importance of considering PMT in the differential diagnosis for unexplained hypophosphatemia and osteomalacia-like symptoms, especially in persistent disease after parathyroidectomy for presumed primary hyperparathyroidism. The atypical immunohistochemical profile observed in this case contributes to the growing body of knowledge about the heterogeneity of PMTs and underscores the need for comprehensive diagnostic approaches in suspected cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.